-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Benzinga·08/25/2026 15:28:27
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.